Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ Study of PI3K/mTOR Dual Inhibitor WXFL10030390 to Evaluate the Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumors or Lymphoma

NCT03730142 is registered in ClinicalTrials.gov with Shanghai Jiatan Pharmatech Co., Ltd as lead sponsor.

NCT NCT03730142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03730142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ Study of PI3K/mTOR Dual Inhibitor WXFL10030390 to Evaluate the Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumors or Lymphoma
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2018
Completion date
July 25, 2020
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer